Landiolol hydrochloride is an ultra-short-acting beta-blocker with a favorable pharmacokinetic profile and safety in patients with tachyarrhythmias.
Landiolol hydrochloride has a shorter elimination half-life than any other beta-blocker, and it can be administered safely to patients with various tachyarrhythmias.
Hirotsugu Atarashi (Tue,) studied this question.